Holen Sie sich die Stockscreener-App
6.225
0.57%
0.035
Schlusskurs vom Vortag:
$6.19
Offen:
$6.2
24-Stunden-Volumen:
665.55K
Relative Volume:
0.29
Marktkapitalisierung:
$374.34M
Einnahmen:
$216.11M
Nettoeinkommen (Verlust:
$-220.47M
KGV:
-1.6661
EPS:
-3.7363
Netto-Cashflow:
$-110.44M
1W Leistung:
+3.92%
1M Leistung:
-9.65%
6M Leistung:
+17.45%
1J Leistung:
+43.76%
1-Tages-Spanne:
$6.12
$6.31
1-Wochen-Bereich:
$6.01
$6.31
52-Wochen-Spanne:
$4.14
$9.94
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Firmenname
Vanda Pharmaceuticals Inc
Sektor
Branche
Telefon
202-734-3400
Adresse
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
6.225 | 372.24M | 216.11M | -220.47M | -110.44M | -3.7363 |
VRTX
Vertex Pharmaceuticals Inc
|
436.69 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.59 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.19 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.62 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.32 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-05 | Eingeleitet | Truist | Buy |
| 2025-11-05 | Eingeleitet | B. Riley Securities | Buy |
| 2024-10-31 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-25 | Herabstufung | Jefferies | Buy → Hold |
| 2021-05-12 | Eingeleitet | BofA Securities | Buy |
| 2021-01-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-03-16 | Herabstufung | Oppenheimer | Perform → Underperform |
| 2020-03-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-08-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-07-25 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2018-12-04 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | Bestätigt | Jefferies | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-09-21 | Fortgesetzt | Oppenheimer | Outperform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2017-09-14 | Bestätigt | Piper Jaffray | Overweight |
| 2017-06-27 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-05-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-04-12 | Eingeleitet | Oppenheimer | Outperform |
| 2016-11-09 | Eingeleitet | Aegis Capital | Buy |
| 2016-10-06 | Fortgesetzt | Jefferies | Buy |
Alle ansehen
Vanda Pharmaceuticals Inc Aktie (VNDA) Neueste Nachrichten
Vanda a new buy at B. Riley on 'historic discount' - MSN
Vanda Pharmaceuticals Q3 Earnings Preview - MSN
Vanda (VNDA) director donates 25,836 shares of common stock - Stock Titan
VNDA: 2026 revenue guidance raised on new launches, with BYSANTI and NEREUS set to drive future growth - TradingView
How The Vanda Pharmaceuticals (VNDA) Investment Story Is Shifting With BYSANTI And Nereus - Yahoo Finance
Vanda Pharmaceuticals stock (US92178N1054): Regulatory setback, sharp drop and rising short interest - AD HOC NEWS
Vanda: A Long-Term Pharma Growth Idea, Despite Q1 Earnings Miss (NASDAQ:VNDA) - Seeking Alpha
Vanda targets $240M-$290M 2026 revenue as it introduces $10M-$30M NEREUS sales outlook - MSN
HC Wainwright Brokers Lower Earnings Estimates for VNDA - MarketBeat
State Street (VNDA) discloses 3.02M shares, 5.1% ownership on 13G - Stock Titan
Earnings call transcript: Vanda Pharmaceuticals Q1 2026 misses EPS forecast, stock drops By Investing.com - Investing.com South Africa
Earnings call transcript: Vanda Pharmaceuticals Q1 2026 misses EPS forecast, stock drops - Investing.com Nigeria
H.C. Wainwright cuts Vanda Pharmaceuticals stock price target on higher costs - Investing.com UK
H.C. Wainwright Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Cuts Target Price to $21 - Moomoo
VNDA Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
HC Wainwright Cuts Vanda Pharmaceuticals (NASDAQ:VNDA) Price Target to $21.00 - MarketBeat
H.C. Wainwright cuts Vanda Pharmaceuticals stock price target on higher costs By Investing.com - Investing.com South Africa
Vanda Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
VNDA SEC FilingsVanda Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences - BioSpace
Vanda Pharmaceuticals (VNDA) Losses Deepen To US$239.5 Million LTM Reinforcing Bearish Narratives - Sahm
VNDA Reports Strong Q1 Growth with New Product Launches - GuruFocus
VNDA Projected Revenue Forecast for 2026 at $258.2 Million - GuruFocus
Vanda Pharmaceuticals 1Q Loss/Shr 82c >VNDA - Moomoo
Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences - Intellectia AI
Truist Financial Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Announces Target Price $18 - Moomoo
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2026 Earnings Call Transcript - Insider Monkey
[10-Q] Vanda Pharmaceuticals Inc. Quarterly Earnings Report - Stock Titan
Vanda Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Vanda: Q1 Earnings Snapshot - theheraldreview.com
Vanda maps out 3 May investor events, including a live webcast - Stock Titan
MSN Money - MSN
Earnings call transcript: Vanda Pharmaceuticals misses Q1 2026 forecasts, stock rises By Investing.com - Investing.com South Africa
Vanda Pharmaceuticals Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Vanda Pharmaceuticals misses Q1 2026 forecasts, stock rises - Investing.com Nigeria
Vanda (VNDA) Q1 2026 Earnings Call Transcript - The Globe and Mail
Document - SEC.gov
VANDA PHARMACEUTICALS INC (NASDAQ:VNDA) Misses Q1 2026 Estimates as Top-Line Growth Slows - ChartMill
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Vanda Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
VANDA PHARMACEUTICALS ($VNDA) Releases Q1 2026 Earnings - Quiver Quantitative
Q1 2026 Vanda Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Vanda Pharmaceuticals (NASDAQ: VNDA) boosts 2026 revenue view on new approvals - Stock Titan
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results - marketscreener.com
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results – Company Announcement - Financial Times
[EFFECT] Vanda Pharmaceuticals Inc. SEC Filing - Stock Titan
How many employees work at Vanda Pharmaceuticals? - Revelio Labs
Vanda Pharmaceuticals Inc. Raises Revenue Guidance for the Full-Year 2026 - marketscreener.com
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 - Quantisnow
Finanzdaten der Vanda Pharmaceuticals Inc-Aktie (VNDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vanda Pharmaceuticals Inc-Aktie (VNDA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Moran Kevin Patrick | SVP, CFO & Treasurer |
Mar 02 '26 |
Sale |
8.27 |
42,442 |
350,821 |
411,380 |
| Wijkstrom Joakim | SVP, Chief Marketing Officer |
Mar 02 '26 |
Sale |
8.27 |
30,800 |
254,590 |
333,469 |
| Polymeropoulos Mihael Hristos | President and CEO |
Mar 02 '26 |
Sale |
8.17 |
156,235 |
1,276,971 |
2,704,496 |
| Birznieks Gunther | SVP, Business Development |
Mar 02 '26 |
Sale |
8.27 |
42,431 |
350,730 |
494,197 |
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):